* Lawsuit alleges Novo's 30-month closing period would stall Metsera's ( MTSR ) obesity drug * Metsera ( MTSR ) says Pfizer ( PFE ) using litigation to lower its takeover price * Judge will analyze claims on Tuesday By Sabrina Valle, Mrinalika Roy and Tom Hals Nov 3 (Reuters) - Pfizer ( PFE ) filed a second lawsuit on...

(Reuters) -Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is designed to suppress competition in obesity drugs.  Novo and Metsera on Monday rejected Pfizer's claims, in a dramatic escalation in the legal and bidding fight for control...

NEW YORK--(BUSINESS WIRE)-- Cantor Equity Partners V, Inc. (the “Company”) announced today the pricing of its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share. The shares are expected to be listed on the Nasdaq Global Market under the symbol “CEPV” and begin trading on November 4, 2025. The underwriters have been granted a 45-day...

WASHINGTON (Reuters) -President Donald Trump's clampdown on the U.S. Consumer Financial Protection Bureau earlier this year has compounded IT security lapses at the agency through the cancellation of contracts, according to an audit report released on Monday. The information security program at CFPB -- which maintains sensitive and confidential data from investigations, the oversight of companies and complaints received from...